Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Repression of IRF-4 target genes in human T cell leukemia virus-1 infection

Abstract

The human T cell leukemia/lymphotropic virus-1 (HTLV-I) is the etiologic agent of adult T cell leukemia (ATL), an aggressive and fatal leukemia of CD4+ T lymphocytes. Interferon regulatory factor-4 (IRF-4) was shown previously to be constitutively expressed in T cells infected with HTLV-1. In this study, we investigated the role of IRF-4 gene regulation in the context of HTLV-1 infection using gene array technology and IRF-4 expressing T cells. Many potential IRF-4 regulated genes were identified, the vast majority of which were repressed by IRF-4 expression. Cyclin B1, a G2-M checkpoint protein identified as an IRF-4 repressed gene in the array, was further characterized in the context of HTLV-1 infection. All HTLV-1 infected cell lines and ATL patient lymphocytes demonstrated a dramatic decrease in cyclin B1 levels; subsequent analysis of the cyclin B1 promoter identified two sites important in IRF-4 binding and repression of cyclin B1 expression. Furthermore, IRF-4-mediated repression of cyclin B1 led to a significant decrease in CDC2 kinase activity in HTLV-1 infected T cells. IRF-4 expression in HTLV-1 infected T cells also downregulated other genes implicated in the mitotic checkpoint as well as genes involved in actin cytoskeletal rearrangement, DNA repair, apoptosis, metastasis and immune recognition. Several of the identified genes are dysregulated in ATL and may provide important mechanistic information concerning pathways critical to the emergence of ATL.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Arthur WT, Burridge K . 2001 Mol. Biol. Cell 12: 2711–2720

  • Bochkareva E, Korolev S, Bochkarev A . 2000 J. Biol. Chem. 275: 27332–27338

  • Brass A, Kehrli E, Eisenbeis C, Storb U, Singh H . 1996 Genes Dev. 10: 2335–2347

  • Brien TP, Depowski PL, Sheehan CE, Ross JS, McKenna BJ . 1998 Mod. Pathol. 11: 870–877

  • Bruick RK . 2000 Proc. Natl. Acad. Sci. USA 97: 9082–9087

  • Campbell M, Chan G, Yen T . 2001 J. Cell Sci. 114: 953–963

  • Cann A, Chen I . 1996 Fields Virology Fields B (ed) 1849 pp Philadelphia: Lippincott-Raven

    Google Scholar 

  • Cannavo G, Paiardini M, Galati D, Cervasi B, Montroni M, De Vico G, Guetard D, Bocchino ML, Picerno I, Magnani M, Silvestri G, Piedimonte G . 2001 Blood 97: 1756–1764

  • Carbone A, Gloghini A, Cozzi MR, Capello D, Steffan A, Monini P, De Marco L, Gaidano G . 2000 Br. J. Haematol. 111: 247–257

  • Carbone A, Gloghini A, Larocca LM, Capello D, Pierconti F, Canzonieri V, Tirelli U, Dalla-Favera R, Gaidano G . 2001 Blood 97: 744–751

  • Chapman HA, Wei Y, Simon DI, Waltz DA . 1999 Thromb. Haemost. 82: 291–297

  • Chatterjee D, Wyche JH, Pantazis P . 2000 Anticancer Res. 20: 4477–4782

  • Chu ZL, Shin YA, Yang JM, DiDonato JA, Ballard DW . 1999 J. Biol. Chem. 274: 15297–15300

  • Clark PR, Menoret A . 2001 Cell Stress Chaperones 6: 121–125

  • Cogswell JP, Godlevski MM, Bonham M, Bisi J, Babiss L . 1995 Mol. Cell. Biol. 15: 2782–2790

  • Dianov GL, Jensen BR, Kenny MK, Bohr VA . 1999 Biochemistry 38: 11021–11025

  • Dib K . 2000 Front Biosci. 5: D438–D451

  • Duell EJ, Millikan RC, Pittman GS, Winkel S, Lunn RM, Tse CK, Eaton A, Mohrenweiser HW, Newman B, Bell DA . 2001 Cancer Epidemiol. Biomarkers Prev. 10: 217–222

  • Edlich RF, Arnette JA, Williams FM . 2000 J. Emerg. Med. 18: 109–119

  • Eisenbeis CF, Singh H, Storb U . 1995 Genes Dev. 9: 1377–1387

  • Gaidano G, Carbone A . 2000 Leukemia 14: 563–566

  • Grumont RJ, Gerondakis S . 2000 J. Exp. Med. 191: 1281–1292

  • Gupta S, Anthony A, Pernis AB . 2001 J. Immunol. 166: 6104–6111

  • Gupta S, Jiang M, Anthony A, Pernis AB . 1999 J. Exp. Med. 190: 1837–1848

  • Hanahan D, Weinberg RA . 2000 Cell 100: 57–70

  • Hapke S, Gawaz M, Dehne K, Kohler J, Marshall JF, Graeff H, Schmitt M, Reuning U, Lengyel E . 2001 Mol. Cell Biol. 21: 2118–2132

  • Himmelmann A, Riva A, Wilson GL, Lucas BP, Thevenin C, Kehrl JH . 1997 Blood 90: 3984–3995

  • Hiscott J, Kwon H, Genin P . 2001 J. Clin. Invest. 107: 143–151

  • Hrdlickova R, Nehyba J, Bose Jr HR . 2001 Mol. Cell Biol. 21: 6369–6386

  • Iida S, Rao PH, Butler M, Corradini P, Boccadoro M, Klein B, Chaganti RSK, Dalla-Favera R . 1997 Nat. Genet. 17: 226–230

  • Imaizumi Y, Kohno T, Yamada Y, Ikeda S, Tanaka Y, Tomonaga M, Matsuyama T . 2001 Jpn. J. Cancer Res. 92: 1284–1292

  • Innocente SA, Abrahamson JL, Cogswell JP, Lee JM . 1999 Proc. Natl. Acad. Sci. USA 96: 2147–2152

  • Israel A . 2000 Trends Cell Biol. 10: 129–133

  • Itoyama T, Chaganti RS, Yamada Y, Tsukasaki K, Atogami S, Nakamura H, Tomonaga M, Ohshima K, Kikuchi M, Sadamori N . 2001 Blood 97: 3612–3620

  • Iwanaga R, Ohtani K, Hayashi T, Nakamura M . 2001 Oncogene 20: 2055–2067

  • Jackman MR, Pines JN . 1997 Cancer Surv. 29: 47–73

  • Jin D-Y, Spencer F, Jeang K-T . 1998 Cell 93: 81–91

  • Johnson DG, Walker CL . 1999 Annu. Rev. Pharmacol. Toxicol. 39: 295–312

  • Kaida A, Ariumi Y, Ueda Y, Lin JY, Hijikata M, Ikawa S, Shimotohno K . 2000 Oncogene 19: 827–830

  • Kamada N, Sakurai M, Miyamoto K, Sanada I, Sadomori N, Fukuhara S, Abe S, Shiraishi Y, Abe T, Kaneko Y . 1992 Cancer Res. 52: 1481–1493

  • Karin M . 1999a J. Biol. Chem. 274: 27339–27342

  • Karin M . 1999b Oncogene 18: 6867–6874

  • Kasai T, Iwanaga Y, Iha H, Jeang KT . 2001 J. Biol. Chem. 29: 29

  • Katula KS, Wright KL, Paul H, Surman DR, Nuckolls FJ, Smith JW, Ting JP, Yates J, Cogswell JP . 1997 Cell Growth Differ. 8: 811–820

  • Lacana E, Ganjei JK, Vito P, D'Adamio L . 1997 J. Immunol. 158: 5129–5135

  • Lemasson I, Nyborg JK . 2001 J. Biol. Chem. 276: 15720–15727

  • Lemoine FJ, Marriott SJ . 2001 J. Biol. Chem. 276: 31851–31857

  • Lengauer C, Kinzler KW, Vogelstein B . 1998 Nature 396: 643–649

  • Leung TW, Lin SS, Tsang AC, Tong CS, Ching JC, Leung WY, Gimlich R, Wong GG, Yao KM . 2001 FEBS Lett. 507: 59–66

  • Lin R, Heylbroeck C, Genin P, Pitha P, Hiscott J . 1999 Mol. Cell Biol. 19: 959–966

  • Liu A, Cerniglia GJ, Bernard EJ, Prendergast GC . 2001a Proc. Natl. Acad. Sci. USA 98: 6192–6197

  • Liu AX, Rane N, Liu JP, Predergast GC . 2001b Mol. Cell. Biol. 21: 6906–6912

  • Lo KW, Zhang Q, Li M, Zhang M . 1999 Biochemistry 38: 7498–7508

  • Louvet-Vallee S . 2000 Biol. Cell 92: 305–316

  • Mamane Y, Heylbroeck C, Genin P, Algarte M, Servant MJ, LePage C, DeLuca C, Kwon H, Lin R, Hiscott J . 1999 Gene 237: 1–14

  • Mamane Y, Sharma S, Grandvaux N, Hernandez E, Hiscott J . 2002 J. Interferon Cytokine Res. 22: 135–143

  • Mamane Y, Sharma S, Petropoulos L, Lin R, Hiscott J . 2000 Immunity 12: 129–140

  • Manjili MH, Wang XY, Park J, Facciponte JG, Repasky EA, Subjeck JR . 2002 Front Biosci. 7: D43–D52

  • Marecki S, Fenton MJ . 2000 Cell Biochem. Biophys. 33: 127–148

  • Marecki S, Riendeau CJ, Liang MD, Fenton MJ . 2001 J. Immunol. 166: 6829–6838

  • Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ, Dutta A . 1996 Cancer Res. 56: 4159–4163

  • Maytin EV, Ubeda M, Lin JC, Habener JF . 2001 Exp. Cell Res. 267: 193–204

  • Meraro D, Hashmueli S, Koren B, Azriel A, Oumard A, Kirchhoff S, Hauser H, Nagulapalli S, Atchison ML, Levi BZ . 1999 J. Immunol. 163: 6468–6478

  • Mittrucker H-W, Matsuyama T, Grossman A, Kundig TM, Potter J, Shahinian A, Wakeham A, Patterson B, Ohashi P, Mak TW . 1997 Science 275: 540–543

  • Molinari M . 2000 Cell Prolif. 33: 261–274

  • Muchardt C, Yaniv M . 2001 Oncogene 20: 3067–3075

  • Murakami H, Furihata M, Ohtsuki Y, Ogoshi S . 1999 Virchows Arch. 434: 153–158

  • Nagulapalli S, Atchison ML . 1998 Mol. Cell. Biol. 18: 4639–4650

  • Neuveut C, Jeang KT . 2002 Front. Biosci. 7: D157–D163

  • Ng T, Parsons M, Hughes WE, Monypenny J, Zicha D, Gautreau A, Arpin M, Gschmeissner S, Verveer PJ, Bastiaens PI, Parker PJ . 2001 EMBO J. 20: 2723–2741

  • Nilsson I, Hoffmann I . 2000 Prog. Cell Cycle Res. 4: 107–114

  • O'Connor PM . 1997 Cancer Surv. 29: 151–182

  • Ohshima K, Suzumiya J, Sato K, Kanda M, Simazaki T, Kawasaki C, Haraoka S, Kikuchi M . 1999 J. Pathol. 189: 539–545

  • Pawlak G, Helfman DM . 2001 Curr. Opin. Genet. Dev. 11: 41–47

  • Pise-Masison CA, Choi KS, Radonovich M, Dittmer J, Kim SJ, Brady JN . 1998 J. Virol. 72: 1165–1170

  • Pise-Masison CA, Mahieux R, Jiang H, Ashcroft M, Radonovich M, Duvall J, Guillerm C, Brady JN . 2000a Mol. Cell Biol. 20: 3377–3386

  • Pise-Masison CA, Mahieux R, Radonovich M, Jiang H, Duvall J, Guillerm C, Brady JN . 2000b AIDS Res. Hum. Retroviruses 16: 1669–1675

  • Porter LA, Singh G, Lee JM . 2000 Blood 95: 2645–2650

  • Poullet P, Gautreau A, Kadare G, Girault JA, Louvard D, Arpin M . 2001 J. Biol. Chem. 276: 37686–37691

  • Rosenbauer F, Waring JF, Foerster J, Wietstruk M, Philipp D, Horak I . 1999 Blood 94: 4274–4281

  • Sadamori N . 1991 Cancer Genet Cytogenet. 51: 131–136

  • Sadamori N, Isobe M, Shimizu S, Yamamori T, Itoyama T, Ikeda S, Yamada Y, Ichimaru M . 1991 Acta Haematol. 86: 14–19

  • Satoh S, Tominaga T . 2001 J. Biol. Chem. 276: 39290–39294

  • Schmidt M, Hochhaus A, Konig-Merediz SA, Brendel C, Proba J, Hoppe GJ, Wittig B, Enhinger G, Hehlmann R, Neubauer A . 2000 J. Clin. Oncol. 18: 3331–3338

  • Seasholtz TM, Majumdar M, Brown JH . 1999 Mol. Pharmacol. 55: 949–956

  • Senderowicz AM . 2000 Oncogene 19: 6600–6606

  • Senderowicz AM, Sausville EA . 2000 J. Natl. Cancer Inst. 92: 376–387

  • Sharma S, Grandvaux N, Mamane Y, Genin P, Azimi N, Waldmann TA, Hiscott J . 2002 J. Immunol. in press

  • Sharma S, Mamane Y, Grandvaux N, Bartlett J, Petropoulos L, Lin R, Hiscott J . 2000 AIDS Res. Hum. Retroviruses 16: 1613–1622

  • Song Y, Wong C, Chang DD . 2000 J. Cell Biochem. 80: 229–240

  • Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, Mao L . 2000 Cancer Res. 50: 4000–4004

  • Sun SC, Harhaj EW, Xiao G, Good L . 2000 AIDS Res. Hum. Retroviruses 16: 1591–1596

  • Suzuki T, Kiato S, Matsushime H, Yoshida M . 1996 EMBO J. 15: 1607–1614

  • Suzuki T, Narita T, Uchida-Toita M, Yoshida M . 1999 Virology 259: 384–391

  • Tanaka Y, Mine S, Figdor CG, Wake A, Hirano H, Tsukada J, Aso M, Fujii K, Saito K, van Kooyk Y, Eto S . 1998 Blood 91: 3909–3919

  • Taylor WR, DePrimo SE, Agarwal A, Agarwal ML, Schonthal AH, Katula KS, Stark GR . 1999 Mol. Biol. Cell 10: 3607–3622

  • Taylor WR, Stark GR . 2001 Oncogene 20: 1803–1815

  • Tirnauer JS, Bierer BE . 2000 J. Cell Biol. 149: 761–766

  • Tsukasaki K, Koeffler P, Tomonaga M . 2000 Baillieres Best Pract. Res. Clin. Haematol. 13: 231–243

  • Tsukasaki K, Krebs J, Nagai K, Tomonaga M, Koeffler HP, Bartram CR, Jauch A . 2001 Blood 97: 3875–3881

  • Vidal AE, Boiteux S, Hickson ID, Radicella JP . 2001 EMBO J. 20: 6530–6539

  • Wang IK, Lin-Shiau SY, Lin JK . 2000 Pharmacol. Toxicol. 86: 83–91

  • Weinert T . 1997 Science 277: 1450–1451

  • Xiao G, Harhaj EW, Sun SC . 2000 J. Biol. Chem. 275: 34060–34067

  • Xiao G, Sun SC . 2000 Oncogene 19: 5198–5203

  • Yamagata T, Nishida J, Tanaka T, Sakai R, Mitani K, Yoshida M, Taniguchi T, Yazaki Y, Hirai H . 1996 Mol. Cell. Biol. 16: 1283–1294

  • Yao J, Wigdahl B . 2000 Front Biosci. 5: D138–D168

  • Yoshida M . 2001 Annu. Rev. Immunol. 19: 475–496

Download references

Acknowledgements

The authors wish to thank Dr Harinder Singh at the Howard Hughes Institute, University of Chicago for IRF-4, Dr William R Taylor, at the Lerner Research Institute, Cleveland Clinic Foundation for cyclin B1 promoter deletion constructs, as well as the many researchers who provided us with antibodies and expression constructs (see Materials and methods). We also thank the members of the Molecular Oncology Group, Lady Davis Institute, McGill University for helpful discussions. This research was supported by grants from the National Cancer Institute with funds from the Canadian Cancer Society and the CIHR of Canada. Y Mamane was supported by CIHR. N Grandvaux and S Sharma are supported by FRSQ fellowship and studentship, respectively. R Lin is supported in part by a Fraser Monat McPherson Fellowship from McGill University and J Hiscott by a CIHR Senior Scientist award recipient.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to John Hiscott.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mamane, Y., Grandvaux, N., Hernandez, E. et al. Repression of IRF-4 target genes in human T cell leukemia virus-1 infection. Oncogene 21, 6751–6765 (2002). https://doi.org/10.1038/sj.onc.1205843

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205843

Keywords

This article is cited by

Search

Quick links